Koji Kamagata1, Tomoya Nakatsuka2, Ryuji Sakakibara3, Yohei Tsuyusaki3, Tomohiro Takamura4, Kanako Sato5, Michimasa Suzuki5, Masaaki Hori5, Kanako K Kumamaru5, Tsutomu Inaoka2, Shigeki Aoki5, Hitoshi Terada2. 1. Department of Radiology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. kkamagat@juntendo.ac.jp. 2. Department of Radiology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Sakura, 285-8741, Japan. 3. Department of Neurology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Sakura, 285-8741, Japan. 4. Department of Radiology, University of Yamanashi, 1111 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan. 5. Department of Radiology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Abstract
INTRODUCTION: The characteristics of dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and amnestic mild cognitive impairment (a-MCI) overlap but require different treatments; therefore, it is important to differentiate these pathologies. Assessment of dopamine uptake in the striatum using dopamine transporter (DaT) single-photon emission computed tomography (SPECT) is the gold standard for diagnosing DLB; however, this modality is expensive, time consuming and involves radiation exposure. Degeneration of the substantia nigra nigrosome-1, which occurs in DLB, but not in AD/a-MCI, can be identified by 3T susceptibility-weighted imaging (SWI). Therefore, the aim of this retrospective observational study was to compare SWI with DaT-SPECT for differentiation of DLB from AD/a-MCI. METHODS: SWI data were acquired for patients with clinically diagnosed DLB (n = 29), AD (n = 18), a-MCI (n = 13) and healthy controls (n = 26). Images were analysed for nigrosome-1 degeneration. Diagnostic accuracy was evaluated for DLB, AD and a-MCI compared with striatal dopamine uptake using DaT-SPECT. RESULTS: SWI achieved 90% diagnostic accuracy (93% sensitivity, 87% specificity) for the detection of nigrosome-1 degeneration in DLB and not in AD/a-MCI as compared with 88.3% accuracy (93% sensitivity, 84% specificity) using DaT-SPECT. CONCLUSIONS: SWI nigrosome-1 evaluation was useful in differentiating DLB from AD/a-MCI, with high accuracy. This less invasive and less expensive method is a potential alternative to DaT-SPECT for the diagnosis of DLB.
INTRODUCTION: The characteristics of dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and amnestic mild cognitive impairment (a-MCI) overlap but require different treatments; therefore, it is important to differentiate these pathologies. Assessment of dopamine uptake in the striatum using dopamine transporter (DaT) single-photon emission computed tomography (SPECT) is the gold standard for diagnosing DLB; however, this modality is expensive, time consuming and involves radiation exposure. Degeneration of the substantia nigra nigrosome-1, which occurs in DLB, but not in AD/a-MCI, can be identified by 3T susceptibility-weighted imaging (SWI). Therefore, the aim of this retrospective observational study was to compare SWI with DaT-SPECT for differentiation of DLB from AD/a-MCI. METHODS: SWI data were acquired for patients with clinically diagnosed DLB (n = 29), AD (n = 18), a-MCI (n = 13) and healthy controls (n = 26). Images were analysed for nigrosome-1 degeneration. Diagnostic accuracy was evaluated for DLB, AD and a-MCI compared with striatal dopamine uptake using DaT-SPECT. RESULTS: SWI achieved 90% diagnostic accuracy (93% sensitivity, 87% specificity) for the detection of nigrosome-1 degeneration in DLB and not in AD/a-MCI as compared with 88.3% accuracy (93% sensitivity, 84% specificity) using DaT-SPECT. CONCLUSIONS: SWI nigrosome-1 evaluation was useful in differentiating DLB from AD/a-MCI, with high accuracy. This less invasive and less expensive method is a potential alternative to DaT-SPECT for the diagnosis of DLB.
Authors: M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry Journal: Brain Date: 1999-08 Impact factor: 13.501
Authors: Ashley K Lotfipour; Samuel Wharton; Stefan T Schwarz; V Gontu; Andreas Schäfer; Andrew M Peters; Richard W Bowtell; Dorothee P Auer; Penny A Gowland; Nin P S Bajaj Journal: J Magn Reson Imaging Date: 2011-10-10 Impact factor: 4.813
Authors: Y Wang; S R Butros; X Shuai; Y Dai; C Chen; M Liu; E M Haacke; J Hu; H Xu Journal: AJNR Am J Neuroradiol Date: 2011-11-03 Impact factor: 3.825
Authors: Daniel Weintraub; Andrew B Newberg; Mark S Cary; Andrew D Siderowf; Paul J Moberg; Galit Kleiner-Fisman; John E Duda; Matthew B Stern; David Mozley; Ira R Katz Journal: J Nucl Med Date: 2005-02 Impact factor: 10.057
Authors: Francesco Roselli; Nicola M Pisciotta; Robert Perneczky; Michele Pennelli; Maria S Aniello; Maria F De Caro; Ermanno Ferrannini; Bruno Tartaglione; Giovanni Defazio; Giuseppe Rubini; Paolo Livrea Journal: Mov Disord Date: 2009-10-30 Impact factor: 10.338
Authors: Luigi Zecca; Luigi Casella; Alberto Albertini; Chiara Bellei; Fabio A Zucca; Mireille Engelen; Andrzej Zadlo; Grzegorz Szewczyk; Mariusz Zareba; Tadeusz Sarna Journal: J Neurochem Date: 2008-07-04 Impact factor: 5.372
Authors: Stefan T Schwarz; Mohammed Afzal; Paul S Morgan; Nin Bajaj; Penny A Gowland; Dorothee P Auer Journal: PLoS One Date: 2014-04-07 Impact factor: 3.240
Authors: S Shams; D Fällmar; S Schwarz; L-O Wahlund; D van Westen; O Hansson; E-M Larsson; S Haller Journal: AJNR Am J Neuroradiol Date: 2017-07-13 Impact factor: 3.825